|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1001 Pennsylvania Avenue NW |
Address2 | Suite 710 |
| City | Washington |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6484-12
|
||||||||
|
6. House ID# 314020000
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Elizabeth Hall |
Date | 10/21/2019 3:00:05 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment)
ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies)
Individual market and exchange stabilization
Prior authorization
Hospital Consolidation
Privacy and Healthcare Cybersecurity
Social Determinants of Health (SDOH)
Association health plans
Mental health and substance use,42 CFR Part 2, Parity and compliance issues
Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630)
Price of prescription drugs
Medical Loss Ratios
Commercial Risk adjustment data validation (RADV)
Senate HELP Committee Lower Health Care Costs Act
Senate Finance Committee Prescription Drug Pricing Reduction Act; HR 3
Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Hall |
|
|
|
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
ACA implementation (exchange operations and functionality, risk mitigation programs, risk adjustment)
ACA reform (reconciliation, individual mandate, cost sharing reduction subsidies, reinsurance transitional policies)
Individual market and exchange stabilization
Prior authorization
Hospital Consolidation
Privacy and Healthcare Cybersecurity
Social Determinants of Health (SDOH)
Association health plans
Mental health and substance use,42 CFR Part 2, Parity and compliance issues
Surprise medical billing; Lower Health Care Cost Act of 2019 (S. 1895), and No Surprises Act (H.R. 3630)
Price of prescription drugs
Medical Loss Ratios
Commercial Risk adjustment data validation (RADV)
Senate HELP Committee Lower Health Care Costs Act
Senate Finance Committee Prescription Drug Pricing Reduction Act; HR 3
Pharmacy Benefit Manager (PBM) operations and practices, Spread pricing, Lower Health Care Cost Act of 2019 (S. 1895)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Hall |
|
|
|
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Advantage (risk adjustment, coding intensity, encounter data, dual-eligible members,
reauthorization of special need plans, star ratings, normalization factors, stars contract
consolidation)
Medicare RAD-V
Mental health and substance use (42 CFR Part 2)
Medicaid managed care
Medicaid expansion
Medicaid reform (block grants, per capita caps)
Medicaid and CHIP reauthorization
Medicaid actuarial soundness
Long-term services and supports
Social Determents of Health (SDOH)
Medicare Part D prescription drug program and Medicare Part D coverage gap (donut hole)
Removal of safe harbor protections for rebates involving prescription drugs and the creation of
new safe harbor protection for certain point-of-sale reductions on price on prescription drugs and
certain Pharmacy Benefit Manager (PBM) service fees
Medicare Part D crosswalk policy
Opioid addiction issues and response (prescription drug monitoring programs)
Medicaid medical loss ratio remittance
Medicaid non-emergency medical transportation
Medicare Advantage Pilot Program in TRICARE
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Hall |
|
|
|
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
To extend the moratorium and/or repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act
Health Insurance Tax Relief Act of 2019 (H.R. 1398)
Jobs and Premium Protection Act (H.R. 2447)
Jobs and Premium Protection Act (S. 80)
Health Insurance Tax Relief Act of 2019 (S.172)
Tax exclusion for employer-sponsored health insurance
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elizabeth |
Hall |
|
|
|
Samuel |
Marchio |
|
|
|
Adam |
Goldberg |
|
|
|
Catherine |
Nabavi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Senate HELP Committee Lower Health Care Costs Act
Senate Finance Committee Prescription Drug Pricing Reduction Act; HR 3
Price of prescription drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Adam |
Goldberg |
|
|
|
Elizabeth |
Hall |
|
|
|
Sam |
Marchio |
|
|
|
Catherine |
Nabavi |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
CSP |
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |